Skip to main content
    I

    iBio, Inc. Common Stock (IBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.71
    -0.02 (-3.42%)

    Market Cap: $51.55M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    iBio, Inc. Common Stock (IBIO) Financials: Revenue, Profit and Cash Flow

    Updated Aug 28, 2026. Financial statements from company filings, amounts in US dollars.

    iBio, Inc. Common Stock reported revenue of $100.00K for the fiscal year ended Jun 30, 2026, down 75.0% from the year before. That year, net income was -$33.04M with a net margin of -33044.0%, operating cash flow was -$23.22M and free cash flow was -$23.80M. The quarter ended Jun 30, 2026 had net income of -$10.60M.

    Revenue and Margins

    Over the 9 years to Jun 2026, revenue fell from $394.00K, a compound annual decline of 14.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 2026$100.00K-75.0%100.0%-35141.0%-33044.0%
    Jun 2025$400.00K+77.8%100.0%-4650.5%-4594.3%
    Jun 2024$225.00KN/A100.0%-7392.9%-11069.8%
    Jun 2023$0-100.0%N/AN/AN/A
    Jun 2022$1.88M-20.5%100.0%-1576.3%-2670.1%
    Jun 2021$2.37M+44.7%38.3%-1312.1%-979.0%
    Jun 2020$1.64M-18.8%57.1%-854.9%-1003.9%
    Jun 2019$2.02M+354.5%100.0%-782.4%-872.0%
    Jun 2018$444.00K+12.7%100.0%-3204.3%-3627.9%
    Jun 2017$394.00KN/A100.0%-3622.8%-4096.2%
    Annual, fiscal years ended Jun 2017 to Jun 2026

    Income Statement

    In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Revenue$100.00K$400.00K$225.00K$0$1.88M$2.37M$1.64M$2.02M$444.00K$394.00K
    Cost of revenue$0$0$0$0$0$1.46M$703.00K$0$0$0
    Gross profit$100.00K$400.00K$225.00K$0$1.88M$909.00K$935.00K$2.02M$444.00K$394.00K
    Research and development$19.64M$8.31M$5.18M$10.33M$9.83M$9.99M$3.57M$5.47M$3.99M$4.12M
    Operating income-$35.14M-$18.60M-$16.63M-$29.34M-$29.70M-$31.11M-$14.00M-$15.79M-$14.23M-$14.27M
    Net income-$33.04M-$18.38M-$24.91M-$65.01M-$50.30M-$23.21M-$16.44M-$17.60M-$16.11M-$16.14M
    EBITDA-$34.30M-$17.48M-$14.26M-$28.23M-$25.49M-$19.93M-$11.76M-$14.04M-$12.52M-$12.60M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    RevenueN/A$0$0$100.00K$200.00K$0$200.00K$0$175.00K$0$0$50.00K
    Gross profitN/A$0$0$100.00K$200.00K$0$200.00K$0$175.00K$0$0$50.00K
    Operating income-$11.38M-$8.37M-$9.45M-$5.95M-$5.20M-$4.88M-$4.42M-$4.11M-$3.41M-$3.63M-$4.50M-$5.10M
    Net income-$10.60M-$7.73M-$8.99M-$5.72M-$5.16M-$4.86M-$4.36M-$3.99M-$7.78M-$3.17M-$8.21M-$5.75M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, cash and equivalents exceeded short-term debt of $0 by $56.40M.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Total assets$99.11M$23.18M$28.73M$41.21M$99.41M$146.97M$94.19M$30.59M$43.08M$36.01M
    Current assets$92.22M$9.72M$15.67M$26.26M$45.07M$104.60M$61.75M$4.81M$16.29M$8.57M
    Cash and equivalents$56.40M$8.58M$14.21M$4.30M$22.68M$77.40M$55.11M$4.42M$15.93M$8.09M
    Total liabilities$13.40M$8.30M$7.41M$25.83M$35.92M$38.40M$37.58M$28.13M$26.92M$27.09M
    Short-term debt$0$830.00K$519.00K$13.10M$22.16M$600.00K$261.00K$213.00K$197.00K$183.00K
    Long-term debtN/AN/A$829.00K$241.00KN/A$0$339.00K$0$24.88M$25.08M
    Shareholder equity$85.71M$14.88M$21.32M$15.38M$63.48M$108.58M$56.62M$2.46M$16.17M$8.91M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$99.11M$85.83M$64.39M$64.16M$23.18M$19.10M$21.70M$24.52M$28.73M$50.15M$34.02M$37.68M
    Total liabilities$13.40M$8.30M$7.83M$8.12M$8.30M$7.72M$7.80M$6.76M$7.41M$25.29M$24.82M$24.47M
    Cash and equivalents$56.40M$47.63M$28.67M$28.11M$8.58M$4.96M$7.01M$11.04M$14.21M$5.30M$2.79M$1.46M
    Shareholder equity$85.71M$77.54M$56.56M$56.04M$14.88M$11.38M$13.89M$17.75M$21.32M$24.86M$9.20M$13.21M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jun 2026.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Operating cash flow-$23.22M-$15.30M-$18.55M-$30.44M-$37.48M-$30.06M-$13.35M-$13.97M-$13.48M-$13.16M
    Capital expenditures$578.00K$16.00K$210.00K$5.74M$7.33M$4.92M$1.08M$920.00K$934.00K$1.32M
    Free cash flow-$23.80M-$15.32M-$18.76M-$36.17M-$44.81M-$34.98M-$14.42M-$14.89M-$14.41M-$14.49M
    Dividends paidN/AN/AN/A$39.00K$50.00K$0$21.56MN/A$0$0
    Share repurchases$5.86M$294.00KN/A$0N/A$4.71M$2.17M$159.00K$1.18M$0
    Investing cash flow-$32.00M$742.00K$906.00K$7.01M-$5.13M-$26.48M-$1.15M-$990.00K-$1.08M-$1.59M
    Financing cash flow$103.05M$8.93M$24.49M$2.30M-$6.13M$78.83M$65.19M$3.45M$22.41M-$170.00K
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$6.23M-$6.08M-$5.24M-$5.67M-$4.62M-$3.10M-$3.87M-$3.71M-$4.85M-$3.65M-$4.71M-$5.34M
    Capital expenditures$19.00K$11.00K$516.00K$32.00K$1.00K$14.00K$1.00K$0$210.00K$0$50.00K$50.00K
    Free cash flow-$6.25M-$6.09M-$5.76M-$5.70M-$4.62M-$3.12M-$3.87M-$3.71M-$5.06M-$3.65M-$4.76M-$5.39M
    Last 12 quarters

    Frequently Asked Questions About IBIO

    What is iBio, Inc. Common Stock's annual revenue?

    iBio, Inc. Common Stock reported revenue of $100.00K for the fiscal year ended Jun 30, 2026.

    How fast is iBio, Inc. Common Stock's revenue growing?

    Revenue was down 75.0% for the fiscal year ended Jun 30, 2026 compared with the year before.

    Is iBio, Inc. Common Stock profitable?

    No. iBio, Inc. Common Stock reported net income of -$33.04M for the fiscal year ended Jun 30, 2026, with a net margin of -33044.0%.

    How much free cash flow does IBIO generate?

    For the fiscal year ended Jun 30, 2026, operating cash flow of -$23.22M minus capital expenditures of $578.00K produced free cash flow of -$23.80M.

    How much debt does iBio, Inc. Common Stock have?

    The balance sheet dated Jun 30, 2026 reported short-term debt of $0 and cash and equivalents of $56.40M.